Delcath Systems (NASDAQ:DCTH) Issues Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Delcath Systems (NASDAQ:DCTH) announced its earnings results on Tuesday. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.10, Zacks reports. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%.

Delcath Systems Stock Performance

NASDAQ DCTH traded down $0.04 during trading hours on Tuesday, hitting $9.48. The company had a trading volume of 291,012 shares, compared to its average volume of 637,719. Delcath Systems has a 52 week low of $8.87 and a 52 week high of $18.23. The firm has a 50 day simple moving average of $10.92 and a 200 day simple moving average of $12.35. The firm has a market capitalization of $331.62 million, a price-to-earnings ratio of 190.60 and a beta of 0.84.

Institutional Trading of Delcath Systems

Large investors have recently modified their holdings of the business. California State Teachers Retirement System bought a new stake in shares of Delcath Systems during the 2nd quarter valued at about $26,000. Tower Research Capital LLC TRC bought a new stake in shares of Delcath Systems during the 2nd quarter valued at about $40,000. Legal & General Group Plc bought a new stake in shares of Delcath Systems during the 2nd quarter valued at about $46,000. The Manufacturers Life Insurance Company bought a new stake in shares of Delcath Systems during the 2nd quarter valued at about $151,000. Finally, Bayesian Capital Management LP bought a new stake in shares of Delcath Systems during the 2nd quarter valued at about $181,000. Institutional investors own 61.12% of the company’s stock.

Analyst Upgrades and Downgrades

DCTH has been the topic of a number of research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Delcath Systems in a research report on Wednesday, October 8th. HC Wainwright set a $30.00 target price on Delcath Systems and gave the company a “buy” rating in a research report on Monday, October 20th. Craig Hallum reaffirmed a “buy” rating and set a $20.00 target price on shares of Delcath Systems in a research report on Tuesday, October 21st. Finally, Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a research report on Sunday, October 12th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.